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The adequate treatment of pain remains one of the major medical challenges. Morphine and other
opioid drugs are most commonly used to counteract moderate to severe pain, but they are also
increasingly accessed by patients with chronic non-malignant pain. To achieve long-term analgesia,
opioid therapy still represents the standard treatment for chronic pain alleviation. This work presents
an overview of current strategies aiming at controlled opioid release. Two important, and intrinsically
linked, features are discussed in detail: the used formulations (i.e. polymer systems) and the applied
drug administration routes. The different administration routes and their associated advantages and
limitations are described. Links between the chemical structure of commonly used opioids and suited
administration modes and formulations are made. This review can potentially give insight into new
opportunities for adequate relief of chronic pain, a societal burden, by means of alternative (non-
)opioid analgesics and may serve as inspiration for future developments in this area.Introduction
Chronic pain remains a major societal burden that is associated
with a decline of normal daily functioning and quality of life. It is
defined as pain that lasts longer than three months and which is
not in relation with any somatic damage. At least 30% of chronic
pain cases evolve from the inadequate treatment of acute postop-
erative pain [1,2]. To provide sustained analgesia in chronic pain
patients, regular administration of drugs is required to ensure that
the next dose of an analgesic is given before the effects of the
previous dose have dissipated. Unfortunately, despite advances in
understanding its etiology and pathophysiology, chronic pain
remains inadequately treated to date. In general, the appropriate
management of chronic pain [3] aims to improve quality of life
and daily function by alleviating not only pain symptoms, but also
comorbid conditions.*Corresponding authors: Madder, A. (annemieke.madder@UGent.be), Hoogenboom, R.
(richard.hoogenboom@UGent.be), Ballet, S. (sballet@vub.ac.be)
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j.mattod.2016.01.016 This review presents an overview of reported administration
routes and polymer systems for the controlled drug delivery of
opioids in the management of chronic pain. The remainder of this
introduction will focus on the treatment of chronic pain by
opioids (Section ‘Treatment of chronic pain’) and extended-release
of opioids for long-term analgesia (Section ‘Extended-release of
opioids for long term analgesia’). The remainder of this review will
provide an overview of the state-of-the-art in controlled opioid
release formulations, organized by method of administration,
including discussion of the types of polymers to obtain control-
led-release (Section ‘Routes of administration’). Each of these
sections starts with a general reflection on the basic polymer
requirements for obtaining sustained release for the different
administration routes.
Treatment of chronic pain
The pharmacotherapy of chronic pain includes use of non-opioid
analgesics, antidepressants, anticonvulsants, scheduled opioidC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/
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eviewanalgesics, and non-scheduled opioid analgesics. For the treat-
ment of moderate to severe pain, opioid analgesic drugs
(see examples in Fig. 1), are most useful [4], and over the past
years, opioid drug prescriptions have increased significantly [5–8].
Indeed, around 90% of patients suffering of chronic pain have
been treated with opioids [4]. The application of opioid analgesics
for chronic pain alleviation is, however, more controversial as
opioid therapy generates adverse effects like addiction, abuse,
respiratory depression, gastrointestinal effects (constipation),
and urologic effects [9]. Opioid use for treating chronic pain
may be justified only in patients who have not responded to
any other therapy, as long term effects of clinical and excessive
use of opioid drugs can affect nearly every organ system of the
body.
Clinically, morphine (Fig. 1) remains the most used analgesic
drug to date [10]. In addition, hydrocodone, oxycodone, hydro-
morphone, oxymorphone and buprenorphine are semi-synthetic
opioid agonists synthesized from codeine, which present the
characteristic phenanthrene-like nucleus [11]. Oxymorphone
has a twofold higher potency in comparison to morphine, a
characteristic that is often used to make sure that the patient will
not develop any breakthrough pain as it can be the case with
morphine due to its lower bioavailability. Buprenorphine, a semi-
synthetic derivative, is a highly potent (100-fold more active than
morphine) partial m-agonist with a moderate addiction potential.
For buprenorphine, there is no contra-indication in case of renal
failure or for elderly patients due to its ceiling effect, as no
respiratory depression occurs. Its metabolites are not accumulated
in the kidneys. Other opioids like methadone, fentanyl and sufen-
tanil are classified as synthetic agonists without the morphinan
core included in their structures. Methadone is a highly lipophilic
synthetic m-opioid agonist with a long, but highly variable half-life
(from 12 to 120 hours). This particular pharmacokinetic property
implies an elevated risk of overdose due to its long duration of
action. Fentanyl and sufentanil are lipophilic opioids with a short
duration of action, but a much higher potency (100 times and
1000 times, respectively) than morphine. The efficacy can be easily
explained by a high lipophilicity, which allows the efficient pene-
tration of the blood brain barrier (BBB). Analogs of fentanyl are
widely used in intravenous, epidural and intrathecal continuous
infusions, but also in transdermal formulations. Fentanyl has no
active metabolites and can safely be used in the case of patients492with renal failure. Whereas fentanyl was not successful in recovery
of surgically induced immunosuppression, buprenorphine has a
more favorable profile, devoid of any intrinsic immunosuppressive
activity [12]. Immune responses from all components of the
immune system, including both the humoral and cell-mediated
components, appear to be suppressed by morphine and other
opioid-like substances.
All opioids described above allow pain relief by binding to and
activating the m-opioid receptors in the central nervous central
(CNS). Even though the plasmatic drug concentration cannot
predict the analgesic effect, it was demonstrated that high doses
provide greater analgesia. Effective plasmatic opioid concentra-
tion is dependent on many factors such as the opioid drug, the
route of administration, the patient and the medical conditions.
Extended-release of opioids for long term analgesia
Prescription opioids are available as short-acting opioid (SAO) and
long-acting opioid (LAO) formulations depending on their clinical
utility. SAOs have a duration of action from 3 to 6 hours, and they
are characterized by a high fluctuation in plasma opioid concen-
trations. Although they are particularly suitable for the treatment
of acute, unstable or intermittent pain, SAOs can also be used
around-the-clock, in the case of more persistent or chronic pain,
for which a regular administration every 3–6 hours is needed.
Indeed, opioids have a high first pass elimination effect in the
liver resulting in metabolites, obtained after hydrolysis, oxidation,
dealkylation or conjugation of the drug, which undergo renal
excretion. Morphine, for example, undergoes a metabolic phase
II conjugation process called glucuronidation that makes mole-
cules more hydrophilic to enhance renal excretion, leaving only
30% available to exert a biological effect. The metabolites mor-
phin-3-glucuronide (highly toxic and causes seizure) and mor-
phine-6-glucuronide (potent metabolite with analgesic effects like
morphine) are both renally excreted. Therefore, older patients
with renal failure are preferentially not treated with long term
administration of morphine. As a consequence of this metabolic
inactivation, and to provide consistent analgesia, opioid adminis-
tration requires frequent dosing to maintain effective plasmatic
drug levels. Otherwise, blood concentrations of opioids can oscil-
late, resulting in inconsistent pain relief. To provide such a con-
sistent pain relief, it is necessary to develop proper drug delivery
systems that can ensure constant opioid blood levels [13,14].
For the treatment of chronic pain, LAOs are intended for a slow
release of opioids and a long duration of action [15–17]. Compared
to SAOs, they are dosed less frequently (i.e. one to three times per
day) [18]. The beneficial effects of LAOs in chronic pain manage-
ment, to improve efficacy, quality of life, and reduced toxicity,
make them more robust in comparison with the impact of SAOs
[19,20].
LAOs formulations use different types of, mostly polymeric,
controlled-release delivery systems that have been called exten-
ded-release, sustained release, delayed release, prolonged action,
long action and slow release. However, there is no specific defini-
tion for each term due to the fact they are inconsistently used in
literature, for example, by companies that marketed them. The
‘extended-release’ (ER) profile is characterized by a release profile
in which the active molecule released in such a way that blood
levels are maintained within the therapeutic window, but below













wtoxic concentrations, over a period up to 35 hours or even longer
(see blue curve in Fig. 2). The therapeutic window includes a
concentration range between the minimum therapeutic concen-
tration represented by a gray line and the red line, which repre-
sents the start of toxic concentrations; the red dotted line is
representative of a minimum concentration beyond which the
risk of side effect appearance is increased. These sustained release
formulations were designed to deliver a first therapeutic dose, to
immediately provide a therapeutic drug plasma concentration,
followed by a constant and slow drug release to maintain the
therapeutic dose required in the blood.
The different extended-release drug formulations (vide infra) are
designed based on the route of administration for which they are
developed, but also on the physicochemical, pharmacokinetic and
pharmacodynamic properties of the drug. For example, opioids
with short half-life such as morphine, oxycodone or hydromor-
phone are excellent candidates for administration via controlled-
release formulations. Ideally, the extended-release drug formula-
tion should release the drug following a zero-order release profile
kinetic (blue curve in Fig. 2). Polymeric materials are of utmost
importance for the development of such controlled drug release
systems [21–25]. To achieve improved drug release profiles and
pharmacological responses, new formulations are continuously
being designed using polymers as carriers for the drugs. In this
way, one can improve the bioavailability of drugs by different
factors such as the physicochemical properties of the drug, the
dosage, the frequency and the route of administration. A wide
variety of drug delivery platforms have been reported based on
polymeric carriers that embed or covalently link the activeFIGURE 2
Schematic representation of opioid plasma concentrations in function of the admpharmaceutical ingredient. Due to the large diversity of such
drugs, the challenge remains in the design of polymers that afford
the desired extended-release profile for a specific drug. Further-
more, the type of polymer that can be used is strongly dependent
on the mode of administration.
Overall, pain management guidelines advise the use of extend-
ed-release (ER) formulations, rather than immediate-release (IR)
formulation because they provide sustained analgesia [26,27]. For
patients suffering from moderate to severe chronic pain, ER for-
mulations represent a viable option for around-the-clock analge-
sia, allowing a simpler dosing schedule (‘less clock-watching’), but
also a more consistent and durable pain relief. An important
additional consideration is that slow release formulations can also
be utilized to prevent abuse of medically subscribed opioids.
Routes of administration
Opioid analgesics can be administered using a variety of routes
(e.g. oral, sublingual and buccal, intranasal, rectal, intravenous,
subcutaneous). The route of administration and the formulation
of the analgesic are dependent on its pharmacokinetic and phar-
macodynamic properties. The availability of more concentrated
dosage forms and controlled-release opioid preparations for oral
and transdermal opioid formulations are among the most recent
innovations in opioid analgesia treatment [28]. However, the wide
variety of opioid drug delivery systems for chronic pain manage-
ment can be confusing, but in some cases there are clear
indications to opt for one specific formulation [29]. To determine
which drug delivery system is most suited, different parameters
need to be considered (e.g. the patient’s ability to use a specificinistration route (IR: immediate-release and ER: extended-release).
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eviewdevice, the efficiency to deliver acceptable concentrations of opi-
oid, and the potential complications associated to the system). The
financial cost of certain formulations and devices is also an
important parameter for patients who need to purchase their
own medications.
Oral administration
Oral opioid administration is the most common, the easiest and
the least invasive delivery system [30]. For patients who are able to
take oral medications, this way of administration is the first choice
[31]. Indeed, no major complications (except known opioid side
effects) are associated with oral administration. The major draw-
back is based on the biotransformation of opioids in the liver, due
to first-pass metabolization of the drug prior to entering the
systemic circulation. Consequently, the dose of morphine taken
orally, for example, needs to be three times higher than the
intravenous or intramuscular dose of morphine. To provide lon-
ger-lasting analgesia, several oral formulations are available for
slow opioid release (Table 1) [30].
For oral administration it is important to design a drug release
formulation to release the drug at the desired place, that is, in the
stomach or in the intestines, which depends on the stability and
uptake mechanism of the drug. If the drug is unstable at the low pH
(1–4) of the stomach, formulations can be coated with an enteric
coating, which contains carboxylic acid groups that are protonated
and insoluble at the low pH of the stomach, and will dissolve in the
higher pH (7–9) range of the intestines. Both water-soluble and
water-insoluble polymer excipients and coatings can be used for oral
administration leading to controlled drug release by (slow) dissolu-
tion of the polymer or by diffusion of the drug through the polymer
matrix. Importantly, water-soluble polymers should not contain
low molar mass polymer fractions as these lower molar mass chains
may be absorbed into the body. Degradability of the polymer is not
required for oral administration. It is important to note that even
though specific formulations for oral ER are developed, this route of
administration remains limited by the formulation’s residence time
in the gastrointestinal tract, which is commonly 5–10 hours. A very
recent development has overcome this limitation based on an
elastic polymer formulation that unfolds in the stomach and slowlyTABLE 1
Analgesics, extended-release formulations for oral administra-
tion, and delivery systems.
Analgesic Dosage form Drug delivery system
Morphine Capsules ER beads SODAS
Morphine Capsules ER pellets
Morphine Tablets ER ContinTM
Oxycodone Tablets ER AcroContinTM
Oxycodone Capsules ER DETERxTM
Oxycodone Capsules ER ORADURW
Hydromorphone Capsules ER
Hydromorphone Tablets ER OROSW, Push-PullTM
Oxymorphone Tablet ER TIMERxTM
Methadone Tablet ER
Hydrocodone Tablet ER OraGuardTM
494degrades over the course of several days or potentially weeks [32].
Different polymeric systems are used as a matrix to coat the active
drug in long-acting formulations [21]. Opioid ER formulations are
available as capsules or tablets in different doses. The difference
between each formulation is related to the pharmacokinetics of the
delivery system, which determine the dose and the dosing interval.
These specific formulations will be discussed in the following para-
graphs, organized based on the released opioid (Table 1).
Extended-release morphine capsules that use SODAS1 (Sphe-
roidal Oral Drug Absorption System) technology [33] are available
for sustained drug release over 24 hours (Fig. 3) [34]. This formu-
lation consists of a gelatin capsule that contains both immediate-
release (IR) and extended-release (ER) beads of morphine in a ratio
of 9:1 (w/w), which allow to reach a therapeutic level of morphine
within 30 minutes (IR beads) while maintaining the plasmatic
concentration for 24 hours (ER beads). This technology is based
on spherical beads with a diameter of 1–2 mm, containing the drug
and the excipient (Fig. 3, in gray), coated with a layer of release
rate-controlling polymers such as a statistical copolymer of ethyl
acrylate, methyl methacrylate and trimethylaminoethyl methac-
rylate chloride, sold under the tradename Eudragit [35] (Evonik
Industries) and also sometimes referred to as an ammonio-meth-
acrylate copolymer (Fig. 3, in blue). The beads are prepared by
coating of a sugar/starch core with morphine and fumaric acid as
excipient followed by the sustained release polymer coating. This
coating is not present for the immediate-release beads. After
administration and dissolution of the gelatin capsules, these coat-
ed beads are exposed to the gastric fluid and water enters the beads
to dissolve the morphine and fumaric acid. The latter is present
both as osmotic agent to ‘drag’ the water into the beads and to
control the pH, making the release rate independent of the pH of
the GI fluid. Even though the polymer coating layer is insoluble in
the GI fluid it controls the morphine release rate by providing a
diffusion barrier.
Other sustained release (SR) pellet systems of morphine have
been marketed under the brand name Kadian [36] and based on
the same SODAS technology. However, the gelatin capsules of
Kadian only contain one type of beads that provide both immedi-
ate and sustained release [37]. The coating used in this system is
formed by an insoluble ethylcellulose layer containing two differ-
ent pore forming agents, namely polyethylene glycol (PEG with a
molar mass of 6000/mol) and a copolymer of ethyl acrylate and
methacrylic acid (Eudragit, Evonik Industries, also known as
methacrylic acid copolymer (type C)). Once the capsule is admin-
istered, the gelatin capsule dissolves and releases the pellets into
the GI fluid. In the acidic medium of the stomach only the PEG is
dissolved forming small pores into the ethylcellulose layer leading
to immediate-release of a small fraction of the morphine. TheFIGURE 3
Representation of ER capsule using SODASW technology.













wcarboxylic acid groups of the ethyl acrylate methacrylic acid
copolymer are protonated at this low pH making it insoluble
during passage through the GI tract, the pH increases in the
intestine leading to the dissolution of the methacrylic acid copol-
ymer resulting in the formation of bigger pores. As such, the drug
can continue to diffuse from the beads, providing a constant
therapeutic concentration of drug over 24 hours.
In contrast to the previous two sustained release formulation
based on rather complex capsules, the Oramorph sustained release
formulation [38] is a relatively simple tablet form based on mixing
the drug with a hydrophilic polymer excipient, hydroxypropyl-
methylcellulose [39]. After mixing and compression, the final
tablets are obtained. Once the tablet enters the GI tract, the fluid
penetrates the tablet, allowing swelling of the polymer, and for-
mation of a viscous gel. The resulting gel network controls the rate
of water diffusion into the matrix but also the drug diffusion out of
the system. Additionally, a second drug delivery mechanism can
occur due to the erosion of the outer part of the matrix. With this
device a therapeutic plasmatic concentration can be maintained
for a period of 8 to 12 hours. A more advanced controlled-release
morphine tablet that is based on the ContinTM delivery system [40]
has also been commercialized. Here, the controlled-release process
is regulated by the interactions between hydrophilic and hydro-
phobic polymers to fine-tune the diffusion of the drug and, thus,
its release rate. In this formulation, morphine is mixed with a
hydrophilic polymer matrix formed by a mixture of hydrophilic
hydroxypropylmethylcellulose and hydrophobic hydroxyethyl-
cellulose. The mixture is hydrated with water or alcohol and then
fixed with a hydrophobic aliphatic alcohol, for example, cetos-
tearyl alcohol which is a mixture of stearyl alcohol and cetyl
alcohol. This hydrophobic component controls the GI liquid
penetration rate. The final tablet form is achieved by adding
tableting aids after compression of uniform granules. The partition
coefficient of morphine between the hydrophilic and the hydro-
phobic parts controls the drug release from the tablet. Once the
tablet comes in contact with the GI liquid, a swelling of the
hydrophilic matrix occurs, giving a viscous gel. The kinetics of
the drug release are directly linked to the swelling of the hydro-
philic polymer matrix, which is controlled by the rate of fluid
penetration through the hydrophobic part. Consequently, the
general rate of drug release is regulated by variation of the ratio
between the hydrophilic and the hydrophobic polymers. Using
this system, morphine can be administered as a twice daily formu-
lation.
Oxycodone controlled-release [41] tablets have been designed
using the AcroContinTM delivery system [42]. The formulation is
based on the same dual polymer matrix as used in ContinTM, vide
supra. This delivery system provides both the immediate and the
extended-release of the drug, which cannot be achieved using the
ContinTM system alone. Instead of using a neutral hydrophilic
polymer, AcroContinTM uses a cationically charged ethyl acrylate,
methyl methacrylate trimethylammnoniumethyl methacrylate
chloride copolymer to control the drug diffusion. Again the system
is fixed with hydrophobic aliphatic alcohols to control the GI
liquid penetration rate within the tablet. This formulation shows
both immediate and sustained release. The immediate-release
comes from the dissolution and the diffusion of the drug that is
located at the surface of the tablet. The extended-release isachieved through the same strategy as the ContinTM system,
the active component is released from particles embedded into
the matrix. This formulation provides a first dose release of 40%
over the first hour, followed by an extended-release for up to
12 hours.
Sustained release of oxycodone has also been developed in a
more tamper-proof ER formulation, using the DETERxTM technol-
ogy [43]. Indeed, opioid abuse after prescription has been discour-
aged through the development of new drug delivery systems
[44,45]. The DETERxTM formulation is specifically designed to
retain its time-release mechanism even after common methods
of tampering (i.e. physical and/or chemical modifications). The
formulation consists of small spherical beads containing oxyco-
done, a fatty acid, and waxy excipients that are charged into a
capsule. Embedding the drug in a hydrophobic environment leads
to diffusion-controlled slow release. This formulation of oxyco-
done is unique in that it is an abuse-deterrent formulation
designed to allow sprinkle-dosing on food or easy passage through
nasogastric and gastrostomy tubes. The intended time-release
profile is maintained by either of these two convenient methods
of administration [46,47].
Similarly, to facilitate tamper-free drug delivery, another exten-
ded-release formulation of oxycodone was developed using the
ORADUR1 system [48,49]. This technology combines extended-
release properties with an improved tamper resistance, limiting
potential abusers to self-administer the drug by crushing, snorting,
injection or inhalation. The capsule is filled with a high viscosity
liquid carrier material and the drug. Herein, this specific formula-
tion the viscous carrier consists of sucrose acetate isobutyrate and a
cellulose acetate butyrate as polymeric thickener, to form a hy-
drophobic viscous fluid that is transformed in a matrix with elastic
properties when it is in contact with an aqueous medium (e.g. GI
fluid) leading to slow diffusion controlled-release.
The first hydromorphone ER formulation (under the brand
name PalladoneTM) was based on a biphasic drug release, combin-
ing both IR and ER over 24 hours [39]. The formulation used a
controlled-release melt extrusion technology. The drug is blended
with a hydrophobic matrix composed of a copolymer of ethyl
acrylate, methyl methacrylate and trimethylammoniumethyl
methacrylate chloride, stearyl alcohol and ethylcellulose. The
matrix controls both the rate of water permeation within the
pellet and the diffusion of the drug from each pellet. The thera-
peutic concentration in the blood is sustained over 24 hours.
Unfortunately, the consumption of alcohol was found not to be
compatible with such capsules. It results in the disruption of the
system, releasing a fatal dose of hydromorphone. Due to the high
risk of overdose, the food drug administration decided to block all
marketing and sales.
Nonetheless, another hydromorphone ER tablet form has suc-
cessfully been developed [50,51]. This formulation uses the osmot-
ic extended-release oral delivery system (OROS1) Push-PullTM
technology [52]. It is the only available ER form of this analgesic
(Fig. 4) [53]. The OROS1 system is suitable for poorly water soluble
compounds. The OROS1 Push-PullTM technology consists of a
drug layer consisting of the drug, polyethylene glycol and
polyvinylpyrrollidone and an osmotic push layer consisting of
polyethylene glycol, sodium chloride and hydroxypropylcellulose
that is coated by a semipermeable shell membrane consisting of495
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eviewcellulose acetate and polyethylene glycol [54]. Once in the GI
tract, the fluid flows through the membrane at a controlled rate,
allowing the push layer to expand and eject the suspended drug
from the drug layer out of the tablet through the delivery orifice.
This formulation provides a sustained release over 24 hours [53].
Interestingly, extended-release oxymorphone tablets were de-
veloped based on a delivery system called TIMERxTM [55]. This
technology is based on a hydrophilic natural polymer based matrix
that consists of xanthan gum, locust bean gum and dextrose.
These polysaccharides form a coat layer around the drug core.
This layer regulates the rate of drug release by controlling the GI
fluid permeation into the tablet and the solubilization/diffusion of
the drug through the tablet. Contact of the hydrophilic layer with
water forms a viscous gel that controls the release of the drug from
the tablet, as previously discussed for the ContinTM technology.
TIMERxTM drug delivery provides sustained analgesia for 12 hours
(Fig. 5) [39].
Hydrocodone ER formulations were developed for the first time
as a single-agent drug using the OraGuardTM drug delivery tech-
nology [56]. The OraGuardTM tamper deterrent and alcohol resis-
tant platform was designed to protect drugs against mechanical
crushing and prevent dose dumping when the drug is taken with
alcohol [57]. Hydrocodone is comminuted with a high polymer
load and coated with a polymeric membrane that controls the
drug release even when the tablet is crushed. This formulation is
still in clinical trials (Phase III) and no details on the polymers used
have been disclosed [58].
Liquid formulations are also available for patients such as
children or elderly patients. The introduction of biocompatible
polymers [59–61] is an alternative for the design and the produc-
tion of modified release formulations. Among adequate polymeric
materials used for drug microencapsulation, significant efforts
have been devoted to the development of hydrophobic ethyl
cellulose as the drug carrier. It has been widely used in liquid oral
pharmaceutical formulations, and is generally regarded as a non-
toxic, nonirritant, safe and stable material. For example, ethylFIGURE 5
Structure and mechanism of the TIMERxTM drug delivery tablet.
496cellulose pseudolatex particles are able to encapsulate morphine
[62] and used for the development of a stable final pharmaceutical
form with diffusion-controlled slow release. Using 1% of carbopol
as the thickener in the suspension’s final formula, 81% of the
initial dose of morphine is released over 8 hours [63].
Oral controlled-release opioid formulations enhance a better
pain relief due to the extended therapeutic blood concentration
and the improvement in dosing intervals. A reduction of blood
drug level fluctuation decreases the appearance of adverse effects
(Fig. 1). The differences between all oral ER opioid drugs are the
cost, the formulation, including the drug release system, and the
excipients. Actually, no data support the higher efficacy of one
drug compared to another one. Selection of the first treatment
relies mainly on the clinician, who usually prescribes one preferred
drug. This preference is sometimes in function of past opioid
responses of the patient. Taking into consideration all the param-
eters such as pain tolerance, drug metabolism and the manage-




Transdermal drug delivery systems are an interesting alternative to
oral delivery technologies because they offer several advantages
over other existing analgesic administration methods [64]. Indeed,
this strategy is non-invasive, simple, safe and effective for pain
management [65]. Additionally, compared to other parenteral
routes, practical drawbacks related to the use of needles and the
required venous access, are avoided. Similar to other parenteral
routes, transdermal drug delivery also by-passes first-pass hepatic
metabolism and circumvents gastrointestinal tract-to-blood pas-
sage, common to the use of oral analgesics. In addition, it can also
provide release profiles during long periods of time, providing an
improvement in patient compliance.
The major challenge for transdermal delivery is the limited
number of molecules that can be formulated for this type of
administration, as passive diffusion of the drug through the stra-
tum corneum is required [66]. These analgesics have to present
certain characteristics, which include a low molecular weight (less
than 500 Da), appropriate partition coefficients and a high poten-
cy (i.e. with low dosage, typically less than milligram doses per
day) [67]. Delivery of hydrophilic drugs using transdermal delivery
is difficult and has not been exploited to date for opiates. There are
also some general considerations for designing polymer based
transdermal patches. These polymers should not be water-soluble
to avoid dissolution and potential interactions with the skin.
Furthermore, they need to be soft and tacky to have good adher-
ence and contact with the skin. This means that the polymer
should have a low glass transition temperature, at least below body
temperature, but preferably even lower to facilitate sufficient chain
mobility for diffusion of the drugs.
Transdermal delivery systems are, according to the penetration
mechanism through the skin, subcategorized in three generations,
only two of which were used in opioid applications. The first
generation of systems gave way to many of today’s patches by
judicious selection of drugs that can cross the skin at therapeutic
concentrations by passive transport. The second generation was
developed to increase the skin permeability of small-molecule













wdelivery using alternative driving forces for the transport (using for
example the iontophoretic transdermal system, vide infra), while
the third generation enabled the delivery of small-molecules,
macromolecules, virus-based and vaccines through the skin’s stra-
tum corneum by more invasive systems (such as microneedles and
microdermabrasion) [64].
Transdermal delivery systems were applied to the management
of chronic pain. Among all molecules which are available to treat
chronic pain, only two (fentanyl and buprenorphine) have been
used in this type of system due to their high potency, high
lipophilicity and low molecular weight. Indeed, due to the very
fast metabolization of fentanyl by enzymes in the small intestine
and the liver, transdermal delivery technologies are highly suited
to provide fast and efficient pain relief.
First generation: reservoir and matrix patches
Fentanyl is a suitable analgesic for transdermal administration
thanks to its physicochemical characteristics. It has a low molecu-
lar weight (286 Da), high lipophilicity (LogP = 717), and optimal
skin flux (around 1000 times higher than morphine) [66].
Different transdermal fentanyl delivery systems [68], patches
that contain a drug reservoir or a drug-infused matrix, rely on skin
penetration by passive diffusion (Fig. 6).
The fentanyl-containing reservoir patch represented the first
opioid transdermal delivery system available in this form and
proved effective and convenient for providing pain relief. This
delivery system contains a reservoir of fentanyl with a sufficient
dose for a three day treatment [69]. It consists of a backing layer,
formed by a polyester film that protects the patch from the
environment, a liquid drug reservoir with dehydrated alcohol
gelled with hydroxyethylcellulose, a membrane, constituted of
an ethylene-vinyl acetate copolymer, which controls the rate of
release of fentanyl from the reservoir, and a silicone adhesive layer
to adhere the patch to the skin surface. The fentanyl release occurs
from the reservoir, at constant rate until the reservoir is emptied.
The rate of fentanyl diffusion across the skin layers is determined
by the properties of the ethylene-vinyl acetate copolymer mem-
brane. The addition of alcohol (0.1 mL/10 cm2) into the formula-
tion also helps to increase the permeability of fentanyl through the
skin. After the initial application of the fentanyl transdermal
system, the skin gradually absorbs fentanyl, resulting in an in-
crease of plasma concentrations. A maximum dose that remains
relatively constant is achieved in 12–24 hours, with only some
small fluctuations, and an efficacy over 72-hour [70]. After patch
removal, fentanyl serum concentrations decline gradually, drop-
ping to 50% in approximately 20–27 hours. The bioavailability ofFIGURE 6
Schematic representation of reservoir and matrix patches; adapted from
[65].transdermally administered fentanyl has been calculated to be
approximately 90% [71]. This percentage depends on the skin
permeability and the body clearance of each patient. The reservoir
patch presented a risk of drug leakage (incidental or intentional by
cutting), and this was clearly considered as an important concern.
To address this concern about the reservoir system, a second
transdermal patch generation was developed. Herein, the drug is
directly dissolved into the matrix, a semi-solid formulation of a
polyacrylate adhesive. Fentanyl matrix patches with a lower drug
load were found to be superior to and as safe as established standard
oral and transdermal opioid treatments [72]. Afterwards, a second
type of matrix patch was developed. In such systems the drug is
dispersed in a semi-solid formulation within the adhesive itself. The
matrix is constituted by fentanyl-containing dipropylene glycol
droplets dispersed in a silicone matrix formulation. This formula-
tion modifies both the drug release profile by extending it, and the
drug loading which can be reduced by 35–50%, compared to other
matrix patches. The rate-controlling membrane ensures that fenta-
nyl concentrations are maintained at a constant level throughout a
72-hour application of the patch. It was shown that the two fentanyl
transdermal delivery systems (reservoir and matrix patches), de-
scribed before, have equivalent properties in terms of tolerability
and bioavailability of the drug [70].
The fentanyl patches present limited side effects that can, gener-
ally, be easily treated. The most important adverse effects reported
are dermatological reactions, such as skin occlusion or local irrita-
tion [69]. A rotation of skin sites can prevent these mild side effects.
For patients suffering of chronic pain, transdermal delivery systems
are well tolerated due to the administration of stable opioid doses.
Some sort of ‘breakthrough’ pain coverage is still advised by, for
example, an immediate-release oral dose of morphine.
Buprenorphine is also available as a matrix patch. It provides
consistent blood drug concentration over a 7-days dosing interval
[73]. A comparison between transdermal fentanyl and transdermal
buprenorphine patches was reported, showing the equal efficacy
[74]. The best treatment seems to switch between the two opioid
formulations to increase tolerance and acceptability by suppres-
sing side effects.
Iontophoretic transdermal system (ITS)
The first generation of patches (vide supra) functions through passive
transdermal diffusion, eventually resulting in a slow absorption of
the drug from the skin depot. One drawback of this approach
consists of the prolonged action after removal of the patch.
To provide a more precise control over the delivery of the
analgesic drug, an alternative system that improves the perme-
ation of the drug through the stratum corneum by using an active
transport was developed. The iontophoresis patch technology was
designed for the management of moderate to severe pain in a
clinical setting (Fig. 7) [75,76].
The iontophoretic system is based on a low intensity electric
current that drives the active transport of analgesic drugs through
the skin and into the systemic circulation. This device uses the skin
to complete the circuit between the anode and the cathode,
allowing transport of ionized active molecules present in a
reservoir. More precisely, the driving force for the displacement
of ionized molecules, is based on the electrostatic-repulsion of
similar charges. Drug delivery by an iontophoretic system is497
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FIGURE 7
Iontophoresis patch technology adapted from [77]. The system is
composed of a plastic top containing the battery and electronics, the
plastic bottom contains two hydrogel reservoirs and a skin adhesive. The
hydrogel located at the anode contains the opioid (blue dots). The other












eview however influenced by several parameters including the skin
surface which is in contact with the electrode, the current inten-
sity as well as the duration, but also the chemical properties of the
molecule. Generally, the best efficiency of this delivery system is
obtained for lipophilic compounds with a low molecular weight
and positive charge [75]. As a consequence, the number of opioids
that can be used for this delivery system is limited [66]. Nonethe-
less, fentanyl is suitable for iontophoretic transdermal delivery,
reaching blood drug concentrations comparable to those obtained
by intravenous infusion [78,79]. In contrast, morphine is not ideal
for use in iontophoretic patches [80,81], due to its low lipophilicity
that prevents skin penetration. The general requirements for the
polymer are similar as described for the first generation patches.
The iontophoresis patch is a patient-controlled analgesia (PCA)
system. Patients could self-administer analgesic doses by pressing
one button depending on their need for pain relief. For example in
the case of fentanyl, a pre-programmed dose delivers 40 mg of drug
over 10 min, with a maximum of six doses per hour. This type of
administration offers several advantages compare to passive trans-
dermal systems, such as an increase of opioid absorption rate, a
rapid decrease in plasmatic concentrations and a more precise
control of dosages.
Several limitations inherent to this transdermal drug delivery
system need to be noted as well. First, the impossibility to modify
the delivered dose during the treatment can become problematic
in case of patients with considerable opioid needs for a suitable
pain relief. The other limitation is associated to the patient-con-
trolled analgesia (PCA) concept, wherein patient involvement is
crucial. The patient needs to be a suitable candidate for pain self-
management, since he/she needs to be able to follow the instruc-
tions for operating the system. Finally, the most significant draw-
back of this technology consists however of the associated price
which has limited its broad applicability. Iontophoretic transder-
mal system marked an evolution in pain management system with
an improvement in terms of safety and convenience, as compared
with existing patient controlled-analgesia, through the use of a
pre-programmed and disposable drug delivery systems [82].
Topical administration
Topical opioid treatments give access to local analgesia with
attenuated or eliminated systemic adverse effects. Results from
case studies and pilot clinical studies on local morphine treatment
for painful skin ulcers, however, have not shown to be fully
convincing with respect to efficacy and tolerability [83–85]. A498major drawback is the required repeated replacement of the
wound dressing, which is very painful for the patient and bears
a risk of destroying any regenerated epithelia. Therefore, the
interval of the changes should be extended as much as possible
and new formulations were still needed.
Various studies dealing with local applications of opioids for the
treatment of painful skin ulcers have been reported [86]. Most of
them show an analgesic effect post administration without side
effects that are normally observed after systemic administration.
Indeed, the potential advantages of such a delivery system include
the possibility to optimize opioid concentration at the site of pain
and decreased systemic opioid levels. For topical formulations, a
morphine solution is generally mixed with a hydrogel containing
2.3% carboxymethylcellulose polymer with 20% propylene glycol,
but other formulations have been used as well [85,87–89]. Unfor-
tunately, this gel-based morphine formulation does not adhere
very well to a moist wound surface.
To improve adhesion, a novel topical preparation of morphine
was formulated using poloxamer 407 (P407), a thermoreversible
gel also known as Pluronic (F127) [90]. The temperature-controlled
self-assembly of poloxamer into micellar structures can yield
hydrogels at sufficiently high polymer concentrations [91]. Polox-
amer 407 is a triblock copolymer consisting, by weight, of approx-
imately 70% polyethylene oxide as outer blocks and 30%
polypropylene oxide as middle block with an average total molec-
ular weight of 12.5 kDa. P407 gels show adequate bioadhesive
properties. The formulation of 0.5% (w/w) morphine–HCl in a
22% (w/w) P407 hydrogel was developed [90]. The observed release
follows zero-order kinetics and is controlled by drug diffusion from
the gel matrix. Morphine–HCl was released at a rate of 150 mg/
cm2/h. These results are in favor of the use of P407 gel as a topical
sustained release formulation for the treatment of painful ulcers
[92], although absorption of these relatively low molar mass
polymers may be a concern.
Parenteral administration
Due to limitations in bioavailability and the formulation chal-
lenges associated with some of these pharmaceuticals, parenteral
drug delivery is an administration route of paramount importance.
This includes intravenous, subcutaneous and intramuscular injec-
tion. Indeed, parenteral administration of opioids is needed in
patients with gastrointestinal tract disorders, when the opioid
need is high or in cases where toxicities associated with intermit-
tent dosing schedules emerge. Morphine sulfate is the most com-
monly used parenteral opioid and it can be administered as a bolus
or continuous infusion. Continuous parenteral administration of
opioids is usually cumbersome and expensive, it needs availability
of vascular or subcutaneous catheters, infusion pumps, and it
requires trained nursing and pharmacy personnel.
Subcutaneous administration route
Subcutaneous administration of opioids can be highly useful for
patients that do not have indwelling intravenous access and
require parenteral opioid administration [93]. Here, the infusion
rates of fluid that can be administrated have been found to be
around two to four milliliters per hours (without generation of
pain at the administration site), which represents the limiting
factor [94]. The main advantage in favor of subcutaneous over













wintravenous analgesic administration is that there is no need for
vascular access. Indeed, the administration sites can easily be
changed and problems associated with indwelling intravenous
catheters are avoided. For local treatments, parenteral administra-
tion of drugs is often associated with poor retention of the phar-
maceutical product at the site of delivery. In case of systemic
delivery, short half-lives can be problematic. To compensate for
these drawbacks, parenteral drug administration is typically done
at high concentrations or at high dosing frequencies. However,
high concentrations of the drug can result in adverse side effects.
To increase the efficacy of parenteral administration one can
make use of delivery vehicles. In this method, the administered
drug is encapsulated within a material that releases the therapeutic
agent in a controlled manner that optimizes the dosage for a
specified period of time. Hence, polymer implants can be used.
Advances in polymer chemistry have resulted in the development
of polymeric delivery devices that reliably release therapeutic
compounds in a controlled and continuous fashion. In this way
a highly biocompatible, non-biodegradable, polymeric device
which releases hydromorphone at a constant rate over four weeks
was developed. This device could improve compliance, minimize
the risks of drug diversion, and provide a low cost alternative for
patients with pain who could benefit from chronic parenteral
opioid infusion [95]. In this formulation hydromorphone is em-
bedded in a controlled-release matrix, namely an ethylene-vinyl
acetate (EVA) copolymer. In the study reported by Lesser et al., the
implant had a cylindrical geometry and measured approximately
0.27 cm in height and 1.05 cm in diameter. Variations in the
thickness and diameter of these devices, as well as in the number
of devices implanted, provides flexibility in the amount of hydro-
morphone released per hour, the duration of hydromorphone
release, and the magnitude of plasma hydromorphone levels.
To avoid the potentially deadly ‘burst effect’ with this type of
devices, a poly(methyl methacrylate) coating has been used. Plac-
ing an uncoated cylindrical channel through the center of the
coated polymer limits the available surface area for drug release,
and allows hydromorphone to be released with near zero-order
kinetics for approximately 4 weeks in preclinical in vitro and in vivo
models. These implants could substantially reduce the need for
pumps, storage or refrigeration, frequent medical or nursing eva-
luations and multiple daily opioid doses.
There are several potential disadvantages linked to the use of
these opioid delivery devices. Placement and removal of these
polymer disks requires a minor surgical procedure. They are
inserted through a small skin incision and advanced into the
subcutaneous tissues. It should be mentioned that this may
be avoided by developing thin tubular implants with a diameter
up to 2 mm that can be simply injected as is done for the con-
traceptive implant ImplanonTM. These implanted hydromor-
phone polymers were developed to meet stable dosing needs of
patients in pain. Acute exacerbations in pain intensity will require
supplemental oral or parenteral opioids. Finally, this polymeric
drug delivery system may not be appropriate for patients requiring
high doses of parenterally administered opioids. As noted above,
the dose of hydromorphone delivered per hour can be modified by
changing the height of the implant and more than one polymer
implant can be placed subcutaneously, as was tested in rabbits to
increase the delivery rate and dosing even further.Clinically, subcutaneous administration of opioids is not pre-
ferred for patients with very high opioid requirements, who may
be best served with another method of opioid delivery or a
combination of methods to provide adequate analgesia.
Continuous infusion
The subcutaneous administration of analgesics is often used in
combination with a pump-based PCA system. This provides a
better control over analgesia by the patient, as compared to the
continuous infusion system alone. The subcutaneous administra-
tion of hydromorphone using a PCA system gives a bioavailability
of around 80% [96]. Steady-state plasma hydromorphone concen-
trations were reached within 24 hours in a study performed by
Moulin and coworkers. When compared to the intravenous route,
subcutaneous PCA administrations avoid the need for vascular
access, and present the possibility to easily change the adminis-
tration site. Alternatively, the analgesic drug can be bound to an
ionic polymer such as hyaluronic acid or poly-g-glutamic acid. The
polymer can be anionic, and the drug cationic, or vice versa. The
polymer-drug matrix can be injected either subcutaneously, intra-
muscularly or intraperitoneally. The matrix is degraded over time
via the enzymatic machinery of the body, thereby releasing the
drug [97].
Intravenous route
The intravenous administration is prescribed for patients whose
pain relief cannot be controlled by less invasive systems. For
patients who need opioid infusion for pain control, nursing sup-
port is required, which generates serious costs. Depending on the
frequency and duration of the treatment, different devices can be
used, such as a Port-a-Cath1 or other types of indwelling central or
peripheral catheters [98]. Any indwelling intravenous catheter can
become a source of infection. Many opioids are commercially
available at various concentrations for intravenous solutions, such
as morphine, hydromorphone, fentanyl and sufentanil. Due to the
above mentioned drawbacks, intravenous administration is only
used in extreme cases, when more common routes are not appro-
priate, for example in advanced cancer, or in palliative care.
Perispinal route
The majority of patients, who suffer of chronic pain, can be
adequately treated by opioid administration using one of the
many systems discussed above. However, in some cases the pain
relief remains troublesome despite large administered opioid
doses. Patients can for example suffer from unmanageable ad-
verse effects such as nausea or oversedation. As last resort, opioids
can be administered as local anesthetics using the perispinal route
[99,100]. Perispinal opioid administration involves the direct
application of a small opioid dose close to the spinal opioid
receptors. The main advantage of this administration system is
the suppression of undesirable effects by decrease of the total
opioid dose.
This way of administration requires the implantation of a
permanent catheter, associated to an external infusion pump,
into the epidural or intrathecal space [101]. Different perispinal
approaches including intrathecal injection, continuous
intrathecal infusion, epidural bolus, and continuous epidural
infusion are available for opioid drug delivery [98].499











eviewThe choice between epidural versus intrathecal application or
external versus implantable pumps to deliver the opioid is based
on several factors such as the type and pain location, the duration
of treatment, the patient preference, etc. The opioid dose required
for epidural administration is around 10 times superior to intra-
thecal administration [102]. Intrathecal opioid delivery allows
higher opioid dose administration due to a focused opioid appli-
cation at the receptor site, generating decreased drug-related
adverse effects. Regarding treatment duration, a therapy exceeding
6 months requires the placement of an intrathecal catheter to limit
refills of the pump.
Different types of side effects are associated to perispinal opioid
delivery. The surgical and procedural complications include bleed-
ing and/or infections [103]. Some complications can originate
from a system malfunctioning, including kinking, obstruction,
disconnection, tearing or migration of the catheter, all of which
can have an influence on the rate of opioid delivery. Finally,
pharmacological side effects such as overdoses can be avoided
by means of precise formulation. Generally, except constipation
which is the most common adverse effect encountered in opioid
treatment, perispinal opioid administration does not generate any
supplementary side effects for patients who are already tolerant to
opioids.
Clearly, this route of administration needs nursing care and a
clinical environment, making this delivery system highly expen-
sive.
Conclusions and perspectives
Chronic pain therapy is a complex pathology with extensive
consequences for the patient and society. The main challenge
with chronic pain therapy is the need for a multidisciplinary
and multipharmaceutical approach, which makes advances in
daily treatment difficult to optimize and follow up. Integration
in chronic pain schemes of newer drugs such as glutamate antago-
nists, vanilloid receptor agonists, acetylcholine and norepineph-
rine modulators, adenosine receptor agonists, anti-inflammatory
drugs will be as important as the administration routes of these
drugs.
Adequate pain relief can significantly improve the quality of life
of these patients and attenuate this societal burden. Chronic pain
management guidelines recommend the use of long-acting, ex-
tended-release analgesics because they provide prolonged, and
more consistent plasma concentrations of drug compared with
short-acting compounds. But before exposing patients to an exten-
ded-release formulation of opioids, they must fulfill certain crite-
ria. The most important of all is that the patients must be opioid
tolerant; meaning that they must consume more than 60 mg of
morphine (or an equivalent) per day for more than seven days.
To manage chronic pain, several opioid delivery systems are
available. Selection of the most efficient, cost-effective and user-
friendly method needs careful consideration. This means that the
patient’s ability to use a specific type of delivery system, the
efficiency of the system, the potential complications associated,
and the cost must be regarded.
Oral administration of opioids is efficient and acceptable for
most of patients suffering of chronic pain. Indeed, a large set of
oral opioid drug formulations is available. Obviously, the main
advantage is the ease of administration. Additionally, various500polymer systems have been applied successfully resulting in sus-
tained release providing longer and gradual pain relief. The major
disadvantage for oral therapy is the first-pass effect and the organ-
dependent metabolism, resulting in the necessity of higher dosage
forms compared to other types of administration. Minor and less
frequent disadvantages occur in patients with dysphagia or neu-
rological impaired persons that cannot swallow.
Alternatively, the transdermal route is useful for highly lipo-
philic opioid such as fentanyl and buprenorphine, whereby the
drug is formulated into a polymer reservoir coated with an adhe-
sive polymer or the drug can directly be formulated with the
adhesive polymer. Fentanyl and buprenorphine are equally effec-
tive, but the latter drug is less addictive. Transdermal patches have
a medium risk for adverse effects and are even approved in chil-
dren older than 2 years. No mg/kg dosing is however used as over-
and under-dosing can occur due to age-related and developmental
changes in pharmacokinetics. Transdermal formulations are often
preferred by patients compared to oral controlled-release options
[104]. The advantages of transdermal therapy in elderly people
include a non-invasive long term administration mode that is
independent from intestinal absorption and circumvents first-pass
effects. A slow attainment of the peak-plasma concentration also
results in improved therapy compliance. Some disadvantages
include skin irritation and the limitation of the drug types that
can be used with this formulation. The dose is also limited by
240 mg/h, without any possibility for dose adjustments outside
the hospital. The second generation of transdermal administra-
tion, the iontophoretic delivery system, has a better control of
dosage, gives a rapid absorption rate and allows fast clearance. It is
important to note that the associated cost of this technique
represented a major drawback for its broad applicability.
Even though topical opioid therapy is not fully established, it
can give analgesia without common opioid side effects. By apply-
ing the drug locally, the total opioid dose can be reduced. The only
drawback is related to the repeated replacement of wound dress-
ing, as the regeneration of epithelia can be damaged. The intrave-
nous opioid administration system is useful for patients whose
pain cannot be controlled by less invasive ways. The intravenous
opioid infusions can be administered by continuous infusion, or
using a patient-controlled analgesic device. The delivery can be
accomplished by central venous access, vein puncture or implan-
tation of a Port-a-Cath1 in the subclavian vein during surgery. The
latter is commonly used in cases of chemotherapy. The major
disadvantages are the risk of infection, the cost and the need of
educated personnel, limiting the patient’s freedom. Finally, for a
limited number of patients, for who adequate analgesia by sys-
temic administration fails, because of side effects like nausea,
sedation and constipation, spinal or epidural dosing via catheters
needs to be considered. The dose is directly injected at the spinal
cord, giving a better analgesia and a reduction of side effects,
which allow a decrease of the total opioid dose. Because this mode
of administration is invasive and accompanied by a significant risk
of infection, it is restricted to the palliative care.
In the future polymer implants can also be employed in pain
therapy. The cylindrical geometry and variations in thickness and
diameter can change the rate of release and total dosing. It is
reliable, controlled, gives a better compliance, and there is less
need for a pump or a daily intake of drugs. The disadvantage is that













wit requires a minor surgical intervention, which may be overcome
in the future by developing thin tubular implants that can be
directly injected. Such a device might present a possible burst-
release effect of the drug, with a risk to lose the implant in the body
due to migration. For the latter, it should be noted that on-demand
drug delivery systems have already been developed and may be
applied for opioid delivery in future developments [105–107].
In the field of drug delivery, nanotechnology aims to formulate
therapeutic agents in biocompatible nanocarriers (roughly 10 to
200 nanometer size range), such as nanoparticles [108], nanocap-
sules, micelles and liposomes, nanotubes and dendrimers. The
major advantage of these formulations is their extended blood
circulation time, in combination with enhanced cellular uptake
especially by non-healthy, cancerous, tissue, also known as the
enhance permeation and retention effect [109]. Furthermore,
functionalization of the nanocarriers with targeting ligands allows
direct drug delivery to the site of action, improving the bioavail-
ability of the drug [110]. In this way, these nanosystems help to
prevent the possible undesired exposure of the drug to off-target
tissues. Although nanotechnology for drug delivery is extensively
used for therapeutics in cancer and inflammation applications, in
the literature only few examples have already been reported for
opioid administration. One example consists of an extended-
release morphine suspension, that uses DepoFoam1 technology
[111]. It is a single dose liposomal formulation of morphine, which
is administered by epidural injection [112]. This formulation is
applied following important surgery, it decreases the need of
repeated systemically administered analgesics, and provides an
efficient pain relief for up to 48 hours after injection. This tech-
nology disperses lipid-based particles that form multivesicular
liposomes containing multiple internal aqueous chambers
[113]. The drug is encapsulated in the water-filled particles afford-
ing a milk-like solution ready to be injected. This example of a
‘nanotherapeutic’ exemplifies further innovations based on nano-
technologies [114].
Clearly, if a new technology could arise that realizes a stable
continuous opioid release system that lasts longer than the state-
of-the-art 72 hour patches; it would represent a tremendous ad-
vancement in chronic pain therapy. It could improve the patient’s
quality of life and compliance by a less timely bound intake of
drugs. Continued research remains of paramount important to
tune the optimized administration format for each patient with
chronic pain.
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